Guidelines: ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors

Guidelines: ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors

2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors

Rather than consider screening test results in isolation, the new ASCCP Management Guidelines use current and past results, and other factors, to create individualized assessments of a patient’s immediate risk of precancer (CIN3+), or 5-year risk of progressing to precancer or cancer. This new framework was designed to adjust to the rapidly emerging science and new technologies as they become available.

To streamline navigation of the guidelines, the ASCCP has released a practical app, available for download from their website. This app further enables you to adjust to the rapidly emerging science for the long-term utility of the guidelines.

The guidelines are supported by 19 professional organizations and patient advocates: American Society for Colposcopy and Cervical Pathology (ASCCP), American Academy of Family Physicians (AAFP), American Cancer Society (ACS), American College of Nurse-Midwives (ACNM), American College of Obstetricians and Gynecologists (ACOG), American Society for Clinical Pathology (ASCP), American Sexual Health Association (ASHA), American Society of Cytopathology (ASC), Centers for Disease Control & Prevention (CDC), Cervivor, College of American Pathologists (CAP), Latino Cancer Institute, National Cancer Institute (NCI), Nurses for Sexual and Reproductive Health (NSRH), Nurse Practitioners in Women's Health (NPWH), Papanicolaou Society of Cytopathology, Society of Gynecologic Oncology (SGO), Team Maureen, Women Veterans Health Strategic Healthcare Group.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

BD blog: The future of cervical cancer screening: More genotypes means more precise care
Cervical Cancer | News & Updates
BD blog: The future of cervical cancer screening: More genotypes means more precise care
Chris Beddard, Vice President, U.S. Marketing, Integrated Diagnostic Solutions at BD
Cervical Cancer | News & Updates
NJBIZ Conversations: Chris Beddard
Politico article
Cervical Cancer | News & Updates
POLITICO: Women don’t know when to get screened for cervical cancer, survey finds